

# Pharmacy and Therapeutics Committee

April 17, 2024



# Prayer



# Approval of Minutes



# Our Lady of Lourdes Health P&T Committee

*Protocol Update*



# Protocol Update

## Fluid Resuscitation in Burn Patients



- Calculations changes making it clear to nursing what to do when calculating fluid needs.
- The flowsheet has changed, building in more stops where the nurse will call the physician and overall tightening up fluid changes by nursing (i.e in the previous process allowed for fluid increases with greater amounts before calling MD; the new process will only allow increases up to 100 mls without a physician call).
- The vital signs parameters will now include a higher heart rate and lower BP threshold to reflect the effects burn shock has on the body and allow more flexibility when deciding on titrating fluids vs initiating pressors if urine output is adequate with this lower BP.
- The plan is to have this order set built in Epic.



# FMOLHS System P&T Committee

Class Reviews



# FMOLHS System P&T Recommendations:

| <b>ANTIDIARRHEAL AGENTS (56:08)</b>                               |               |
|---|---------------|
| Bismuth subsalicylate   | FORMULARY     |
| diphenoxylate/atropine  |               |
| Loperamide  |               |
| Crofelemer, difenoxin/atropine, opium tincture, telotristat ethyl | NON-FORMULARY |

| <b>ALPHA-GLUCOSIDASE INHIBITORS (68:20.02):</b> |               |
|---|---------------|
| Acarbose, miglitol                              | NON-FORMULARY |



# FMOLHS System P&T Recommendations:

| GLP-1 RECEPTOR AGONISTS (68:20.06)  |   |
|---|---|
| Liraglutide (Victoza®)  | FORMULARY - <i>restricted to continuation of a home medication in pediatrics.</i> |
| Dulaglutide (Trulicity®), exenatide (Byetta®), lixisenatide (Adlyxin®), semaglutide (Ozempic®, Rybelsus®), Liraglutide (Saxenda®), liraglutide/insulin degludec (Xultophy®), lizisenatide/insulin glargine (Soliqua®) | NON-FORMULARY   |



# FMOLHS System P&T Recommendations:

| <b>BILE ACID SEQUESTRANTS (24:06.04)</b>                                     |               |
|--|---------------|
| Cholestyramine, colesevelam  | FORMULARY     |
| Colestipol   | NON-FORMULARY |
| <b>SCABICIDES/PEDICULICIDES</b>  |               |
| Permethrin   | FORMULARY     |
| Crotamiton, malathion, ivermectin,<br>pyrethrin/piperonyl/butoxide, Spinosad | NON-FORMULARY |



# FMOLHS System P&T Recommendations: UPDATES

- Barbiturates (28:24.04)
  - updated to include Pentobarbital
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (8:18.08)
  - Vemlidy (tenofovir alafenamide) added to formulary for hepatitis B patients
- Alpha-Adrenergic Blocking Agents (24:08.4)
  - Prazosin added with restriction to use in PTSD and Nightmares
- Protease Inhibitors (PIs) (8:18.08)
  - Keletra (lopinavir/ritonavir) oral solution will be restricted to Pediatrics
- Anticonvulsants Succinimide (28:12.20)
  - Ethosuximide oral suspension will be formulary restricted to pediatrics



# FMOLHS System P&T Recommendations:

| BOTULINUM TOXINS (92:92):              |   |
|--|---|
| OnabotulinumtoxinA (Botox ®)           | FORMULARY (inpatients)  |
| OnabotulinumtoxinA (Botox ®)           | FORMULARY (outpatients) – <i>preferred</i>  |
| All other products                     | FORMULARY - <i>alternatives</i>   |
| ALPHA-1 PROTEINASE INHIBITORS (48:92): |   |
| Prolastin C                            | FORMULARY – <i>preferred, restricted to outpatient use</i>                        |
| Aralast NP, Glassia, Zemaira           | FORMULARY – <i>restricted to outpatient as alternatives as insurance requires</i> |



# FMOLHS System P&T Recommendations:

## ASTHMA BIOLOGICS (48:10.20, 48:92)

Cinqair (reslizumab), Fasenra (benralizumab), Nucala (mepolizumab), and Dupixent (dupilumab), Xolair (omalizumab), Tezpire (tezepelumab)

FORMULARY – *restricted to outpatient*

## NEURAMINIDASE INHIBITORS (8:18.28, 8:18.92)

Oseltamivir

FORMULARY

Peramivir

FORMULARY - *restricted to adult and pediatric infectious disease providers within 48 hours of symptom onset*

Zanamivir, baloxavir

NON-FORMULARY



# FMOLHS System P&T Recommendations:

| COMPLEMENT INHIBITORS, ANGIOEDEMA TREATMENT (92:32) |  |
|---|--|
| Berinert and Firazyr                                | FORMULARY  |
| Ruconest and Kalbitor                               | NON-FORMULARY  |
| Cinryze, Haegarda, Orladeyo, and Takhzyro           | FORMULARY - <i>restricted to outpatient</i>                                  |
| COMPLEMENT INHIBITORS, C5 and C3 (92:21.08)         |  |
| Soliris   | FORMULARY - <i>restricted to inpatient use for hemolytic uremic syndrome</i> |
| Ultomiris   | FORMULARY - <i>preferred outpatient</i>                                      |
| Empaveli and Veopoz                                 | NON-FORMULARY  |



# FMOLHS System P&T Committee

Automatic Interchange proposals



- Kcentra to Balfaxar conversion proceeded in Epic on April 2, 2024
- Will continue to use Kcentra until stock depleted



# FMOLHS System P&T

## Automatic Interchange Proposals

*\*\*these will only be implemented after validation through testing in the EPIC test environment to avoid disrupting the continuity of the EPIC Beacon treatment plans.*

| Medication Ordered (Brand Name)                           | Formulary Medication   | Dose and Frequency |
|---|--|--------------------|
| Bevacizumab 25 mg/mL intravenous solution (Avastin)       | BEVACIZUMAB-BVZR 25 MG/ML<br>INTRAVENOUS SOLUTION<br>(Zirabev)       | Same as Ordered    |
| Bevacizumab-awwb 25 mg/mL intravenous solution (Mvasi)    |  |                    |
| Bevacizumab-maly 25 mg/mL intravenous solution (Alymsys)  |  |                    |
| bevacizumab-adcd 25 mg/mL intravenous solution (vegzelma) |  |                    |
| Trastuzumab 150 mg intravenous solution (Herceptin®)      | TRASTUZUMAB-DKST 150 MG & 420 MG<br>INTRAVENOUS SOLUTION<br>(Ogivri) | Same as ordered    |
| Trastuzumab-anns 150 mg intravenous solution (Kanjinti)   |  |                    |
| Trastuzumab-anns 420 mg intravenous solution (Kanjinti )  |  |                    |
| Trastuzumab-dttb 150 mg intravenous solution (Ontruzant)  |  |                    |
| Trastuzumab-dttb 420 mg intravenous solution (Ontruzant)  |  |                    |
| Trastuzumab-pkrb 150 mg intravenous solution (Herzuma)    |  |                    |
| Trastuzumab-pkrb 420 mg intravenous solution (Herzuma)    |  |                    |
| Trastuzumab-qyyp 150 mg intravenous solution (Trazimera)  |  |                    |
| Trastuzumab-qyyp 420 mg intravenous solution (Trazimera)  |  |                    |

# FMOLHS System P&T

## Automatic Interchange Proposals

*\*\*these will only be implemented after validation through testing in the EPIC test environment to avoid disrupting the continuity of the EPIC Beacon treatment plans.*

| Medication Ordered | Brand Name | Dosage form | Dose and Frequency | Formulary Medication                     | Dosage Form | Dose and Frequency      |  |
|--------------------|------------|-------------|--------------------|--|-------------|-------------------------|--|
| pegfilgrastim 6mg  | Neulasta   | Injection   | As Ordered         | <b>pegfilgrastim-jmdb<br/>(Fulphila)</b> | Injection   | Same as Ordered         |  |
| pegfilgrastim-cbqv | Udenyca    | Injection   |                    |  |             |                         |  |
| pegfilgrastim-bmez | Ziextenzo  | Injection   |                    |  |             |                         |  |
| pegfilgrastim-apgf | Nyvepria   | Injection   |                    |  |             |                         |  |
| pegfilgrastim-fpgk | Stimufend  | Injection   |                    |  |             |                         |  |
| pegfilgrastim-pbbk | Fylnetra   | Injection   |                    |  |             |                         |  |
|                    |            |             |                    |  |             |                         |  |
| Filgrastim         | Neupogen   | Injection   | 300 mcg daily      | <b>TBO-Filgrastim<br/>(Granix)</b>       | Injection   | Same Dose and frequency |  |
|                    |            |             | 480 mcg daily      |  |             |                         |  |
| Filgrastim-SNDZ    | Zarxio     | Injection   | 300 mcg daily      |  | Injection   |                         |  |
|                    |            |             | 480 mcg daily      |  |             |                         |  |



# FMOLHS System P&T

## Automatic Interchange Proposals

*\*\*these will only be implemented after validation through testing in the EPIC test environment to avoid disrupting the continuity of the EPIC Beacon treatment plans.*

| Medication Ordered (Brand Name)                          | Dosage form | Formulary Medication                  | Dosage Form | Dose and Frequency |
|--|-------------|---------------------------------------|-------------|--------------------|
| INFILIXIMAB 100 MG INTRAVENOUS SOLUTION (Remicade)       | Injection   | INFLIXIMAB-ABDA 100 MG<br>(Renflexis) | Injection   | Same as ordered    |
| INFILIXIMAB-DYYB 100 MG INTRAVENOUS SOLUTION (Inflectra) | Injection   |                                       |             |                    |
| INFILIXIMAB-AXXQ 100 MG INTRAVENOUS SOLUTION (Avsola)    | Injection   |                                       |             |                    |
|  |             |                                       |             |                    |
| RITUXIMAB-ABBS 10 MG/ML INTRAVENOUS SOLUTION (Truxima)   | Injection   | RITUXIMAB-PVVR<br>(Ruxience)          | Injection   | Same as ordered    |
| RITUXIMAB-ARRX 10 MG/ML INTRAVENOUS SOLUTION (Riabni)    | Injection   |                                       |             |                    |
| RITUXIMAB 10 MG/ML CONCENTRATE,INTRAVENOUS (Rituxan)     | Injection   |                                       |             |                    |



# FMOLHS System P&T Committee

Consent Agenda Class Review  
Recommendations Summary



# FMOLHS System P&T Consent Agenda Class Review Recommendations Summary

| Antihemorrhagic Agents |  |
|------------------------|--|
| Praxbind               | FORMULARY – <i>for reversal of life-threatening dabigatran ICH</i> |
| Andexanet alfa         | NON-FORMULARY  |

| Loop Diuretics                                    |               |
|---|---------------|
| Furosemide, ethacrynic acid injection, bumetanide | FORMULARY     |
| Torsemide, ethacrynic acid tablets                | NON-FORMULARY |



# FMOLHS System P&T Consent Agenda Class Review Recommendations Summary

| Thiazide Diuretics  |  |
|---|--|
| Hydrochlorothiazide, Chlorthalidone, Metolazone, chlorothiazide injection | FORMULARY                                  |
| Chlorothiazide oral solution  | FORMULARY - <i>restricted to PICU/NICU</i> |
| Chlorothiazide tablets, indapamide  | NON-FORMULARY                              |
| Diuretics, Misc   |  |
| Triamterene/HCTZ, spironolactone  | FORMULARY                                  |
| Eplerenone, Triamterene, Amiloride, spironolactone/HCTZ, amiloride/HCTZ   | NON-FORMULARY                              |



# FMOLHS System P&T Consent Agenda Class Review Recommendations Summary

| Calcium Channel Blockers, Non-Dihydropyridine  |                                    |
|--|------------------------------------|
| Diltiazem XL and IR, Verapamil IR and injection  | FORMULARY                          |
| Verapamil ER and Diltiazem SR (12-hour)  | NON-FORMULARY                      |
| Calcium Channel Blockers, Dihydropyridine  |                                    |
| Amlodipine, nifedipine IR, nifedipine XL, clevidipine, nicardipine Injection, nimodipine | FORMULARY                          |
| Isradipine   | FORMULARY-restricted to pediatrics |
| Levamlodipine, nicardipine tablets, nifedipine SR (12-hour), felodipine, & nisoldipine   | NON-FORMULARY                      |



# FMOLHS System P&T

## Consent Agenda Class Review Recommendations Summary

| Benzodiazepines   |  |   |
|---|--|---|
| Clonazepam, diazepam oral and injection, lorazepam, temazepam, chlordiazepoxide, alprazolam IR, midazolam                     |  | FORMULARY                                   |
| Diazepam rectal gel (Diastat®)  |  | FORMULARY - <i>restricted to pediatrics</i> |
| Clobazam  | <i>FORMULARY - restricted to the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older &amp; home medication continuation</i> |   |
| Estazolam, flurazepam, quazepam, triazolam, alprazolam XR, oxazepam, clorazepate, midazolam (Nayzilam®) & diazepam (Valtoco®) |  | NON-FORMULARY                               |



# FMOLHS System P&T Consent Agenda Class Review Recommendations Summary

Update  
4/2024

| Alpha-Adrenergic Blocking Agents                  |   |
|---|---|
| Doxazosin, phentolamine, & tamsulosin             | FORMULARY   |
| Prazosin  | FORMULARY - restricted to use in PTSD and Nightmares  |
| Alfuzosin, silodosin, phenoxybenzamine, terazosin | NON-FORMULARY   |
| 5-alpha Reductase Inhibitors                      |   |
| Finasteride                                       | FORMULARY   |
| Dutasteride & Dutasteride/Tamsulosin              | NON-FORMULARY   |
| Antivirals, topical                               |   |
| Abreva (Doconasol)                                | FORMULARY   |
| Acyclovir ointment                                | FORMULARY-restricted as an alternative to doconasol when application to a large surface area is required. |
| Xerese & Denavir                                  | NON-FORMULARY   |



# FMOLHS System P&T Consent Agenda Class Review Recommendations Summary

Update  
4/2024

| Antiretroviral, Nucleoside Reverse Transcriptase Inhibitors (NRTIs)  |   |
|--|---|
| Abacavir (Ziagen) tablets<br>Emtricitabine (Emtriva) capsules<br>Lamivudine (Epivir) tablets and oral solution<br>Tenofovir disoproxil fumarate (Viread) tablet<br>Zidovudine (Retrovir)<br><b>Tenofovir alafenamide (Vemlidy)</b> | FORMULARY                                   |
| Emtricitabine (Emtriva) oral solution<br>Tenofovir dioproxil fumarate (Viread) oral powder   | FORMULARY – <i>restricted to pediatrics</i> |
| Abacavir (Ziagen) oral solution<br>Zidovudine (Retrovir) tablet and capsule<br>Stavudine (Zerit)<br>Tenofovir alafenamide (Vemlidy)  | NON-FORMULARY                               |



# FMOLHS System P&T Recommendations:

| Antiretroviral, Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)   |   |
|--|---|
| Efavirenz (Sustiva)<br>Doravirine (Pifeltro) tablet<br>Nevirapine (Viramune) oral solution<br>Rilpivirine (Edurant) tablet   | FORMULARY                                   |
| Efavirenz (Sustiva) capsule<br>Etravirine (Intelence)  | NON-FORMULARY                               |
| Antiretroviral, Protease Inhibitors (PIs)  |   |
| Atazanavir (Reyataz)<br>Darunavir (Prezista) tablet<br>Ritonavir (Norvir) tablet, oral powder  | FORMULARY                                   |
| Lopinavir/ritonavir (Keletra)  | FORMULARY – <i>restricted to pediatrics</i> |
| Darunavir (Prezista) oral solution, ritonavir (Norvir) capsule and oral solution, fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), saquinavir (Invirase), tipranavir (Aptivus) | NON-FORMULARY                               |

Update  
4/2024



# FMOLHS System P&T Recommendations:

| Antiretroviral, Integrase Strand Transfer Inhibitors (INSTIs) |   |
|---|---|
| Dolutegravir (Tivicay) tablet                                 | FORMULARY                                   |
| Raltegravir (Isentress/Isentress HD) tablet                   |   |
| Raltegravir (Isentress/Isentress HD) oral powder              | FORMULARY - <i>restricted to pediatrics</i> |
| Dolutegravir (Tivicay) chewable tablet                        | NON- FORMULARY                              |
| Raltegravir (Isentress/Isentress HD) chewable tablet          |   |
| Antiretroviral, Entry Inhibitors                              |   |
| Fostemsavir (Rukobia), maraviroc (Selzentry)                  | NON-FORMULARY                               |



# FMOLHS System P&T Recommendations:

| <b>Antiretroviral Single-Dose Regimens, INSTI + 2 NRTIs</b>           |  |
|---|--|
| Biktarvy (bictegravir + emtricitabine + tenofovir AF)                 | FORMULARY                                    |
| Genvoya (elvitegravir + cobicistat + emtricitabine + tenofovir AF)    |  |
| Triumeq (dolutegravir + abacavir + lamivudine)                        |  |
| Stribild (elvitegravir + cobicistat + emtricitabine + tenofovir DF)   | NON-FORMULARY                                |
| <b>Antiretroviral Single-Dose Regimens, INSTI + NRTI</b>              |  |
| Cabotegravir + rilpivirine (Cabenuva)                                 | FORMULARY – <i>restricted to outpatients</i> |
| <b>Antiretroviral Single-Dose Regimens, NNRTI + 2 NRTIs</b>           |  |
| Atripla (efavirenz + emtricitabine + tenofovir DF)                    |  |
| Symfi, Symfi Lo (Efavirenz/tenofovir disoproxil fumarate/ lamivudine) |  |
| Delstrigo (doravirine + tenofovir disoproxil fumarate + lamivudine)   |  |
| Odefsey (rilpivirine + emtricitabine + tenofovir AF)                  | NON-FORMULARY                                |
| Complera (rilpivirine + emtricitabine + tenofovir DF)                 |  |



# FMOLHS System P&T Recommendations:

| Anticonvulsants, Pyrrolidine                                |   |
|---|---|
| Levetiracetam (Keppra) injection, IR tablets, oral solution | FORMULARY   |
| Levetiracetam (Keppra) ODT and ER tablets                   | NON-FORMULARY   |
| Brivaracetam (Brivailact) injection, tablets, oral solution | FORMULARY – <i>restricted to failed levetiracetam therapy, continuation of home mediation, or neurology</i> |

| Anticonvulsants, Succinamide |   |
|------------------------------|---|
| Ethosuximide oral capsules   | FORMULARY                                   |
| Ethosuximide oral suspension | FORMULARY – <i>restricted to pediatrics</i> |
| Methsuximide                 | NON-FORMULARY                               |

Update  
4/2024



# FMOLHS System P&T Recommendations:

| Anticonvulsants, Valproates                         |   |
|---|---|
| Valproate sodium injection                          | FORMULARY                                   |
| Valproic acid capsules and oral solution            |   |
| Divalproex sodium, all dosage forms                 |   |
| Anticonvulsants, miscellaneous 2                    |   |
| Lamotrigine IR tablets                              | FORMULARY                                   |
| Lamotrigine dispersible tablets for oral suspension | FORMULARY – <i>restricted to pediatrics</i> |
| Lamotrigine ODT and XR                              | NON-FORMULARY                               |
| Cenobamate  |   |



# FMOLHS System P&T Recommendations:

| Anticonvulsants, miscellaneous 3   | FORMULARY                                   |
|--|---|
| Lacosamide (Vimpat) tablets and injection<br>Lacosamide (Vimpat) oral suspension<br>Perampanel (Fycompa) tablet<br>Zonisamide (Zonegran, Zonisade) capsule | FORMULARY                                   |
| Perampanel (Fycompa) oral suspension<br>Zonisamide (Zonegran, Zonisade) oral suspension  | FORMULARY – <i>restricted to pediatrics</i> |



# FMOLHS System P&T Recommendations:

## Angiotensin II (Giapreza)

Angiotensin II (Giapreza)

NON-FORMULARY

## Rolvedon

Rolvedon

FORMULARY – *restricted to outpatient*



# FMOLHS System P&T Recommendations:

| Simethicone Formulations  |  |
|---|--|
| Simethicone 80 mg chewable tablets<br>Simethicone 40 mg/0.6mL infant gas relief | FORMULARY                                |
| All other simethicone formulations  | NON-FORMULARY                            |
| Ophthalmic Agents, Nonsteroidal Anti-inflammatory Drugs (NSAIDs)                |  |
| Ketorolac 0.5% ophth soln   | FORMULARY                                |
| Ketorolac/phenylephrine (Omidria), flurbiprofen                                 | FORMULARY-restricted to ocular surgeries |
| Bromfenac, diclofenac, and nepafenac  | NON-FORMULARY                            |
| Ophthalmic Agents, Mast Cell Stabilizers  |  |
| Ketotifen ophth soln  | FORMULARY                                |
| Alcaftadine, bepotastine, cromolyn, nedocromil, olopatidine                     | NON-FORMULARY                            |



# FMOLHS System P&T Recommendations:

| Ophthalmic Agents, Antiglaucoma, Beta-Adrenergic Blocking Agents |  |
|--|--|
| Timolol 0.5% ophthalmic solution                                 | FORMULARY  |
| Timolol 0.25% ophth soln   | FORMULARY- <i>restricted to pediatrics</i>   |
| Timolol 0.25% ophth gel-forming solution                         | FORMULARY- <i>restricted to infants with hemangioma that cannot take propranolol</i> |
| Betaxolol, carteolol, levobunolol                                | NON-FORMULARY  |

| Ophthalmic Agents: Prostaglandins |               |
|-----------------------------------|---------------|
| Latanoprost 0.005% solution       | FORMULARY     |
| All other agents                  | NON-FORMULARY |



# FMOLHS System P&T Recommendations:

| <b>Ophthalmic Agents, Alpha<sub>2</sub> Agonists</b>  |               |
|---|---------------|
| Brimonidine 0.2% ophth soln   | FORMULARY     |
| Brimonidine 0.025%, 0.1%, 0.15%, 0.2% ophth soln<br>Apraclonidine ophth soln                          | NON-FORMULARY |
| <b>Ophthalmic Agents, Carbonic Anhydrase Inhibitors</b>   |               |
| Dorzolamide ophth soln  | FORMULARY     |
| Brinzolamide ophth soln   | NON-FORMULARY |
| <b>Ophthalmic Agents, Glaucoma Combination</b>  |               |
| Brimonidine/timolol (Combigan), dorzolamide/timolol (Cosopt),<br>brinzolamide/brimonidine (Simbrinza) | NON-FORMULARY |



# FMOLHS System P&T Consent Agenda Class Review Recommendations Summary

| Hemostatic Agents: Factor VII   |                                      |
|---|--------------------------------------|
| NovoSevenRT (coagulation factor VIIa, recombinant)  | FORMULARY                            |
| Sevenfact (coagulation factor VIIa, recombinant-incw)   | NON-FORMULARY                        |
| Hemostatic Agents: Factor VIII  |                                      |
| Humate (antihemophilic Factor/von Willebrand Factor Complex)  | FORMULARY                            |
| Advate (antihemophilic Factor Recombinant)  | FORMULARY- <i>restricted to peds</i> |
| Kogenate FS (antihemophilic Factor Recombinant), Helixate FS (antihemophilic Factor Recombinant), Kovaltry (Antihemophilic Factor Recombinant), Nuwiq (antihemophilic Factor Recombinant), NovoEight (antihemophilic Factor Recombinant), Recombinate (antihemophilic Factor Recombinant), Xyntha (antihemophilic Factor Recombinant), & Obizur (Antihemophilic Factor Recombinant, porcine derived), Koate (Antihemophilic Factor (Human)), Hemotil (antihemophilic Factor (Recombinant)), Jivi (PEGylated-auc1, antihemophilic Factor (Recombinant)), Adynovate (PEGylated, antihemophilic Factor (Recombinant)), Afstyla (single chain, antihemophilic Factor (Recombinant)), Eloctate (antihemophilic Factor (Recombinant), Fc Fusion Protein), & Esperoct (antihemophilic Factor (Recombinant), glycopegylated-exe), Alphanate (antihemophilic Factor/von Willebrand Factor Complex) | NON-FORMULARY                        |



# FMOLHS System P&T

## Consent Agenda Class Review Recommendations Summary

| <b>Hemostatic Agents: Factor IX</b>   |               |
|---|---------------|
| All agents will be non-formulary  | NON-FORMULARY |
| <b>Hemostatic Agents: von Willebrand Factor</b>   |               |
| Humate-P (Antihemophilic factor VIII/von Willebrand factor complex)   | FORMULARY     |
| Alphanate (Antihemophilic factor VIII/von Willebrand factor complex), Wilate (Antihemophilic factor VIII/von Willebrand factor complex), & Vonvendi (von Willebrand factor recombinant) | NON-FORMULARY |



# FMOLHS System P&T

## Consent Agenda Class Review Recommendations Summary

| Beta Blockers   |   |
|---|---|
| Carvedilol (IR), labetalol, propranolol (IR), sotalol, Atenolol, metoprolol tartrate, metoprolol succinate ER, esmolol  | FORMULARY   |
| Carvedilol CR, nadolol, propranolol LA, propranolol ER, timolol acebutolol, betaxolol, nebivolol, metoprolol tartrate/HCTZ, metoprolol succinate/HCTZ, bisoprolol/HCTZ, atenolol/HCTZ, & propranolol/HCTZ | NON-FORMULARY<br><i>See therapeutic substitutions</i> |
| Intranasal Steroids   |   |
| Fluticasone propionate  | FORMULARY   |
| Beclomethasone, ciclesonide, mometasone, flunisolide, fluticasone furoate, triamcinolone acetonide, budesonide, azelastine/fluticasone propionate   | NON-FORMULARY<br><i>See therapeutic substitutions</i> |



# FMOLHS System P&T Consent Agenda Class Review Recommendations Summary

## Inhaled Corticosteroids

All agents NON-FORMULARY- *See therapeutic substitutions*

## Inhaled Selective Beta-2 Adrenergic Agents

All agents NON-FORMULARY- *See therapeutic substitutions*

## Inhaled Anticholinergic Agents

All agents NON-FORMULARY- *See therapeutic substitutions*



# FMOLHS System P&T Committee

Antimicrobial Stewardship



# Adult CRRT & SLED Antimicrobial Automatic Renal Dosing Protocol

